HOME >> BIOLOGY >> NEWS
Imaging apparatus characterizes drops in 'dirty' laboratory environments

CHAMPAIGN, Ill. - A high-fidelity spectrometric system for studying the behavior of drops and particles in industrial flame reactors has been constructed by researchers at the University of Illinois at Urbana-Champaign in collaboration with researchers at the University of Arizona. The instrument was used to study the potential of thermal combustors for reducing the volume of liquid nuclear wastes for safe, long-term storage.

Vitrification of radioactive waste into glassy solids is the most popular approach for disposal. By spraying radioactive sludge into a high-temperature combustor, essentially all the water and other nonradioactive material could be removed, leaving only the radioactive metallic elements to be vitrified for burial. Under optimized conditions, up to 99.99 percent of the metal ions in a waste stream can be scavenged in the combustor.

"That kind of efficiency would be great for most applications, but it's not good enough when dealing with radioactive waste," said Alexander Scheeline, a professor of chemistry at Illinois. "Understanding the cause of the unscavenged fraction and devising a way to reduce it are essential if thermal processing is to be used for nuclear waste treatment."

One possible explanation is that large "rogue" drops are responsible for the unscavenged metals, Scheeline said. These drops do not pass through the hottest zones in the combustor, resulting in only partial vaporization.

To investigate the role of rogue drops in this process, Scheeline and his colleagues -- Illinois postdoctoral researcher Jerry Cabalo, Arizona professor and head of chemical and environmental engineering Jost Wendt, and Arizona graduate student John Schmidt -- developed an optical system to monitor drop sizes and trajectories at very high spatial resolutions.

"In the thermal waste destruction process, small particle formation is also very important," Scheeline said. "Metals released into the gas phase readily
'"/>

Contact: James E. Kloeppel
kloeppel@uiuc.edu
217-244-1073
University of Illinois at Urbana-Champaign
20-Sep-2002


Page: 1 2

Related biology news :

1. Imaging the healing heart
2. Imaging study shows brain maturing
3. Imaging the brain solving problems through insight
4. Imaging technique reveals new structure in retinal cells
5. Imaging technique discovered at Stanford monitors cancer cell proliferation
6. Imaging technique may help in confirming, monitoring treatment of malignant brain tumors
7. Imaging study provides new information on how the brain processes sounds of different tones
8. New Imaging Technique Pinpoints Dead Heart Muscle
9. Imaging Studies Illuminate Brains Response To Cocaine
10. Yale scientists give the Golgi apparatus its own identity, paving the way for more targeted cancer research
11. Procedure, new apparatus may allow relief from incontinence

Post Your Comments:
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ... of the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major ... demand for medical sensors in biomedical applications. Chemical ... quick and correct diagnosis during surgical procedures. The ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "Global Facial Recognition ... http://photos.prnewswire.com/prnh/20130307/600769 ... identification of individuals. Facial recognition system measures the ... nose, jaw edges, mouth, and the distance between ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
(Date:12/17/2014)... 2014 Ipsen Biopharmaceuticals, Inc., an ... IPSEY), today announced that Somatuline® Depot® ... was approved by the U.S. Food and Drug ... tumors (GEP-NETs) in adult patients with unresectable, well ... to improve progression-free survival (PFS). , “The approval ...
(Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)... 2014  Vermillion, Inc. (NASDAQ: VRML ), ... announced the next step in its expanded strategy to ... with the naming of current Chief Operating Officer, ... while current Chairman of the Board and CEO ... These changes are effective January 1, 2015. ...
(Date:12/17/2014)... Calif. , Dec. 17, 2014 ... a Phase 2 study evaluating the investigational oral ... of patients with severe, chronic itch who are ... of care, including topical steroids and antihistamines. ... change in Visual Analog Scale (VAS) itch score ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
Cached News: